CDKN2A and cancer: Using HNSCC as an example, this cancer type displays widespread genetic alterations that include inactivating mutations of the tumor suppressor TP53 (70% of the cases) and mutations, homozygous deletions and promoter methylation of CDKN2A (49%), which are believed to be prerequisites for tumor formation27.